Indian Clinicians’ Perspectives on Utilizing Dapagliflozin-Based Combination Therapy for the Management of Obesity in Patients With Type 2 Diabetes Mellitus

Most Indian clinicians recognize the importance of obesity management in patients with T2DM. However, patient noncompliance and pill burden were identified as significant barriers to managing obesity in these patients. There is a preference for dapagliflozin+metformin FDCs in the management of overweight T2DM patients. Thus, prescribing FDCs in routine clinical practice and ensuring patient access could improve the outcomes in this high-risk group.